The oncology services at ILBS provide an evidence-based multidisciplinary diagnostic and therapeutic applications to patients with cancer. The emphasis is on gastrointestinal/hepatopancreaticobiliary malignancies and other related tumors like neuroendocrine tumors, GIST, and GI lymphoma. Consultation and treatment for other malignancies like urogenital, lung, lymphoma, leukemia, head and neck, breast, gynaecological and brain tumors is also available. While the treatment strategy is scientific and evidence-based, it is also individualized considering patient’s social and economic profiles. Palliative care is an essential component along-with the cancer-directed therapy. In view of the increasing number of cancer patients in ILBS, hospital based cancer registry has been initiated under the National Centre for Disease Informatics and Research, ICMR.
Medical Oncology services include a 9-bedded chemotherapy daycare and a 3-bedded inpatient ward. The department provides screening, diagnosis and treatment for cancers affecting the digestive and other systems. The list of gastrointestinal cancers include liver, gall bladder, bile duct, pancreas, esophagus, stomach, colon, rectum, anal canal etc. Other malignancies like lymphoma, leukemia, sarcoma, lung, kidney, breast cancers etc are also under the purview of the department. Evidence-based chemotherapy protocols as per standard guidelines are followed. Chemotherapy is administered with good supportive treatment and a tender loving nursing care. Targeted molecular therapy is practiced as per scientific evidence.
Radiation Oncology services include a state-of-the-art linear accelerator for the evidence-based treatment of cancers with external radiotherapy. The department is completely equipped with 4-D CT simulator, TPS, and mould room. Provisions for advanced technologies with IGRT, SBRT, IMRT, and 3-DCRT are available. Management of all cancers requiring radiotherapy is under the scope of the department. Advanced treatment with SBRT for hepatopancreaticobiliary cancers is a special area of expertise at ILBS. Focused radiation delivery to the tumor target with sparing of normal tissues is the intent of radiotherapy for providing best outcome and quality of life to the cancer patients. The department is also going to procure brachytherapy in near future.
Nuclear Medicine department has been recently established. With advancements in technology and research, management of various cancers are being increasingly directed at the molecular and cellular levels in the form of targeted therapies. The assessment of disease status and response rates are increasingly being relied upon functional and metabolic signatures over and above the morphological changes. The need for a more precise diagnosis/prognostication of diseases and personalized medicine has moved the entire world like never seen before. And ILBS is no exception. As a result, ILBS has established a dedicated Nuclear Medicine Department with a state-of-the-art 128-slice time-of-flight PET-CT. The uniqueness of PET-CT lies on its ability to noninvasively assess diseases at the metabolic and molecular levels. Moreover, the institute is procuring a 16-slice state-of-the-art SPECT-CT machine. In addition, the department would also be equipped with a 4-bedded high dose Nuclear Medicine therapy ward for Peptide Receptor Radionuclide Therapy (PRRT) and other high dose Nuclear Medicine therapies. Subsequently, the institute is committed to deliver the services of a full-fledged Nuclear Medicine Department to the public for better diagnosis/prognostication of diseases and personalized medicine, both for clinical and academic research purposes.
|Day care Chemotherapy||893||963|
• Technical Training courses in biobanking- Under development
|Course||Candidates admitted||Candidates passed|
|Post Doctoral Certificate Course in HPB/GI Oncology||No. of seats - 2|
- Multi-institutional clinical trial: Comparison of Chemotherapy or Chemoradiotherapy in Adjuvant Treatment of non-pancreatic Peri Ampullary Carcinoma - A Randomized Controlled Trial: CAPR study. Received ethical clearance
- International clinical trial: Perioperative Chemotherapy Prior to and After Reoperation for Incidental Gallbladder Cancer – An International, Randomized Phase III Trial. Applied for ethical clearance
- Inter departmental project: Genome wise association study for evaluating the genetic/epigenetic landscape of cholelithiasis and gall bladder cancer . Applied for ethical clearance
- Intra departmental project: An Open Label Randomized Controlled Trial to compare Metronomic Chemotherapy with Best Supportive Care Versus Best Supportive Care alone in pancreatobiliary cancers. Applied for ethical clearance
- Hospital Based Cancer Registries – Data Management Software under National Centre for Disease Informatics and Research, Bengaluru
- Dr Kumar Alagappan, Prof. and Head, - Dept of Oncologic Emergency MD Anderson cancer centre, USA
- Prof. Milind Javle, Dept of Medical Oncology, , - MD Anderson Cancer Centre
- Dr Shishir K. Maithel, Associate Professor , - Winship Cancer Institute Atlanta, USA